Matinas Biopharma Cash Flow - Quarterly (NYSEMKT:MTNB)

Add to My Stocks
$0.42 $0 (0%) MTNB stock closing price Sep 18, 2018 (Closing)

The Matinas Biopharma cash flow statement helps investors understand how well the company is managing its cash flows. The profit-loss statement shows Matinas Biopharma profits, the balance sheet shows Matinas Biopharma debt, and the cash flow statement reflects the liquidity and solvency of a firm. This statement reflects the company's ability to generate cash flows. Matinas Biopharma had cash and cash equivalents of $8M at beginning of the quarter and $9.54M at quarter end of 2018 Q2. Matinas Biopharma cash flow analysis tells whether or not the company has enough cash for its day to day activities, and for investing for future growth. The cash from operating activities for Matinas Biopharma is $ 2018 Q2, which saw a decrease from previous quarter.

View and download details of Matinas Biopharma cash flows for latest & last 40 quarters
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow----------
Net Increase (Decrease) in Assets Liabilities--0.5M--0.07M-0.01M--0.09M---
Cash From (used in) Discontinued Operations----------
Other Adjustments Net2.33M1.76M3.39M2.33M1.68M1.37M1.52M1.27M--
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-0.26M-0.1M-0.94M-0.82M-0.78M----0.03M-
Acquisition Disposition of Subsidiaires----------
Increase (Decrease) in Investments----------
Other Cash Inflow (Outflow) from Investment Activities----------
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares7.06M-15.68M14.83M14.83M14.83M8.31M8.24M--
Issuance (Repayment) of Debt Securities-0.19M-0.13M-0.34M-0.21M-0.12M-0.07M-0.16M-0.08M--0.01M
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities-------1.15M-1.15M--
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash----------
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year8M4.1M3.22M2.59M10.84M-----
Cash & Equivalents at Year End9.54M4.95M7.3M9M11.26M15.83M4.1M6.21M-1.67M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

While Matinas Biopharma stock price history provides the price history of a stock, Matinas Biopharma stock comparison chart shows the same in comparison to peers, and cash flow statements provide cash position of the company. Common terms used in the statement of cash flows are:

  • Net Change in Cash and Cash Equivalents: A positive net change in cash and cash equivalents shows that Matinas Biopharma is able to meet its expenditure and grow cash at hand which demonstrates the financial strength of the company's balance sheet. Also see - Matinas Biopharma stock price movement.
  • Cash Flow from operating activities: Operating activities include the core business activities. This line item refers to the cash generated from the same and stood at a negative value of $-5.06M for MTNB.
  • Cash Flow from investment activities: Matinas Biopharma used $-0.26M cash due to investment activities. It includes the use of cash outside of normal day to day activities like buying fixed assets, plant and machinery etc.
  • Cash Flow from financing activities: The cash inflow/outflow from financing activities was $6.87M for Matinas Biopharma. The money accounted for under this head comes from external sources which includes lenders, investors and shareholders. Positive cash flow is generated when the company gets cash because of issuance of stocks or bonds. Similarly negative cash flow is generated when shares are repurchased, dividend payments are made, and loans or interest on loans are paid back.

Key Financial Ratios For Matinas Biopharma Cash Flow